Logo

LSTA

Lisata Therapeutics, Inc.

LSTA

Lisata Therapeutics, Inc. • NASDAQ
$2.06 ▲ 0.49% (+0.01)
Market Cap $18.17 M
52w High $4.20
52w Low $1.81
Dividend Yield 0%
P/E -0.97
Volume 13.80K
Outstanding Shares 8.82M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $4.414M ▼ $-4.249M ▲ 0% ▲ $-0.49 ▲ $-4.205M ▲
Q2-2025 $70K ▲ $4.938M ▼ $-4.659M ▲ -6.656K% ▼ $-0.54 ▲ $-4.615M ▲
Q1-2025 $0 ▼ $5.847M ▼ $-4.724M ▼ 0% ▲ $-0.55 $-5.804M ▼
Q4-2024 $1M ▲ $5.949M ▲ $-4.61M ▲ -461% ▼ $-0.55 ▲ $-4.908M ▲
Q3-2024 $0 $5.336M $-4.93M 0% $-0.59 $-5.294M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $18.998M ▼ $21.759M ▼ $4.64M ▲ $17.373M ▼
Q2-2025 $21.97M ▼ $25.16M ▼ $4.385M ▲ $21.029M ▼
Q1-2025 $25.833M ▼ $28.981M ▼ $3.879M ▼ $25.356M ▼
Q4-2024 $31.245M ▼ $35.002M ▼ $5.685M ▲ $29.571M ▼
Q3-2024 $35.856M $38.199M $4.763M $33.69M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.249M ▲ $-3.342M ▲ $5.15M ▲ $353K ▲ $2.163M ▲ $-3.342M ▲
Q2-2025 $-4.659M ▲ $-3.956M ▲ $505K ▼ $64K ▲ $-3.382M ▼ $-3.984M ▲
Q1-2025 $-4.724M ▼ $-5.402M ▼ $9.431M ▲ $-23K ▲ $4.008M ▲ $-5.43M ▼
Q4-2024 $-4.61M ▲ $-4.528M ▼ $1.389M ▲ $-96K ▼ $-3.3M ▲ $-4.528M ▼
Q3-2024 $-4.93M $-2.518M $-6.305M $0 $-8.784M $-2.518M

Five-Year Company Overview

Income Statement

Income Statement Lisata is essentially a pre‑revenue, clinical‑stage biotech. Over the last several years it has generated almost no recurring product revenue, while consistently posting operating and net losses. The loss levels are fairly modest in absolute terms for a biotech, and they have narrowed somewhat recently, but earnings per share remain clearly negative. Overall, this is a classic early‑stage R&D profile: the business is spending to develop its pipeline without yet having any commercial products to offset those costs.

Balance Sheet

Balance Sheet The balance sheet is light but simple: small total assets, mostly made up of cash and related items, with no financial debt reported. Shareholders’ equity has drifted down, reflecting ongoing losses and the absence of significant new asset buildup. The lack of leverage reduces financial risk, but the modest asset and cash base also means the company is likely sensitive to timing and success of future capital raises or partnerships to sustain its programs.

Cash Flow

Cash Flow Cash flows show a steady pattern of cash being used rather than generated. Operating cash flow has been consistently negative, in line with funding clinical trials and R&D. Capital spending is minimal, so free cash flow is essentially the same as operating cash flow and is also negative each year. In practical terms, the company relies on external financing, collaborations, or other non‑operating sources to replenish cash while it advances its pipeline.

Competitive Edge

Competitive Edge Lisata’s competitive position rests on its specialized technologies rather than on market share, since it has no approved products yet. The CendR Platform and lead candidate certepetide are aimed at making other cancer drugs work better by improving penetration into solid tumors, which is a differentiated angle versus many direct cancer‑killing therapies. Strong intellectual property, early but encouraging data in very hard‑to‑treat cancers, and partnerships with firms like Catalent and GATC support its scientific and strategic position. At the same time, as a small clinical‑stage player, it competes against far larger oncology and cell‑therapy companies, and its future standing will depend heavily on upcoming trial results and its ability to secure strong commercial partners.

Innovation and R&D

Innovation and R&D Innovation is the core of Lisata’s story. The company is developing two main platforms: the CendR technology for targeted drug delivery into solid tumors, and CD34+ cell therapies aimed at repairing blood flow in ischemic conditions. The CendR approach, especially certepetide, is notable because it is intended as an “enhancer” that can be combined with many existing oncology treatments, which expands its potential use cases and partnering options. The CD34+ programs offer diversification into regenerative medicine, although they are earlier and less visible than the oncology work. Collaborations that apply artificial intelligence to drug discovery and link CendR with advanced antibody‑drug conjugates show a willingness to experiment at the frontiers of R&D, but all of this remains high‑risk and heavily dependent on clinical and regulatory success.

Summary

Lisata is a small, clinical‑stage biotechnology company with a strong focus on innovation and a very early‑stage financial profile. It currently has negligible revenue, recurring losses, and ongoing cash outflows tied to R&D, but also a clean balance sheet without debt and a lean operating model. The investment case centers almost entirely on the success of its CendR platform in solid tumors and its CD34+ cell therapies, supported by patents and strategic collaborations. Key uncertainties include clinical trial outcomes, regulatory pathways, and continued access to capital. In short, this is a high‑risk, high‑uncertainty, pre‑commercial biotech where future value depends much more on scientific progress and partnering than on current financial performance.

NEWS

November 6, 2025 · 4:05 PM UTC

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 6, 2025 · 8:00 AM UTC

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Read more

November 4, 2025 · 4:00 PM UTC

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Read more

October 30, 2025 · 8:00 AM UTC

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Read more

October 13, 2025 · 8:00 AM UTC

Lisata Therapeutics to Present at LD Micro Main Event XIX

Read more